GlobalData on MSN7 小时
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
Fintel on MSN14 小时
Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation
Fintel reports that on November 14, 2024, Citigroup initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous ...
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
Benzinga.com2 天
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung ...
Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Regeneron股价触及52周低点785.31美元
Regeneron Pharmaceuticals Inc. (REGN)股价已触及52周低点，交易价格为785.31美元。这一价格水平反映出过去一年来股价出现了0.43%的微小但显著下跌，表明这家以创新药物闻名的生物技术公司正处于整固期。投资者正密切关注该股在这一低点的表现，考虑公司的业绩以及可能影响未来几个月走势的潜在市场动向。 在其他近期新闻中，Regeneron Pharmaceutica ...